ERBB2 and cancer: In summary, while zanidatamab shows considerable potential in treating HER2-positive cancers, ongoing research is essential to establish its long-term benefits, address resistance mechanisms, and optimize its role in improving outcomes for patients facing these difficult-to-treat malignancies.